12.6 C
New York
Friday, April 26, 2024

Morgan Stanley Initiates Myriad Genetics With Underperform

Courtesy of Benzinga.

Related MYGN
Crescendo Bioscience To Feature New Data On Vectra DA At 2014 ACR Meeting
Earnings Scheduled For November 4, 2014

Analysts at Morgan Stanley initiated coverage on shares of Myriad Genetics (NASDAQ: MYGN) with a Underperform rating.

The target price for Myriad Genetics is set to $25.

Myriad Genetics shares have gained 29.61% over the past 52 weeks, while the S&P 500 index has surged 14.68% in the same period.

Myriad Genetics’ shares fell 1.98% to $34.20 in pre-market trading.

Latest Ratings for MYGN

Date Firm Action From To
Nov 2014 Morgan Stanley Initiates Coverage on Underperform
Aug 2014 Credit Suisse Maintains Neutral
Jun 2014 Macquarie Maintains Neutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Morgan StanleyInitiation Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,317FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x